Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio.
Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism.
Cypex’s products are produced using a patented technology, which was developed by the University of Dundee in partnership with several leading international pharmaceutical companies. This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.
Cypex’s product portfolio contains more than 115 recombinant enzymes, including CYPs, UGTs, CES, and AOX, and companion chemicals and media. The company also offers services for inhibition screening, protein expression and drug metabolite generation. This work goes towards generating in vitro data showing how a candidate drug will be metabolised in the human body, data often included in new drug applications to regulatory agencies.
“We are delighted that the Cypex team is joining BioIVT, bringing with them not only their market-leading products, but also their in vitro drug metabolism technology expertise,” said BioIVT Chief Executive Officer Richard Haigh. “The acquisition of Cypex enhances BioIVT’s product portfolio, ensuring that we continue to meet all our biopharmaceutical customers’ research requirements for their entire R&D pipeline.”
“This is a good match. We view BioIVT as a like-minded partner; we share the same commitment to supplying high quality products and passion for ensuring that our customers have the best products for their research,” said Dr. Michael Voice, Co-lead Scientist at Cypex. “We are excited that our customers will gain access to BioIVT’s hepatocytes and other hepatic products, and benefit from its well-established global biospecimen network, and robust supply chain.”